Google’s venture arm leads Spero’s $51.7M round for R&D work on a pipeline of new antibiotics
Cambridge, MA-based Spero Therapeutics has completed a C round worth $51.7 million, with Google’s venture arm leading the fundraising for a biotech initially seeded at Atlas.
The money will be earmarked for the company’s work on new antibiotics. Investigators have moved into the clinic with SPR741, which used Spero’s platform potentiator tech to puncture the cell membranes of Gram-negative bacteria, opening a new door for Gram-positive antibiotics.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters